Yes, Zepbound is tirzepatide. Eli Lilly sells the same molecule under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. The active ingredient, strength options, injection schedule, and core side-effect profile are essentially the same; only the FDA-approved indication and packaging differ.
Same Molecule, Two Brand Names
Tirzepatide is a once-weekly subcutaneous injection that activates two incretin receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Activating both pathways slows gastric emptying, improves insulin secretion, reduces appetite, and lowers blood glucose. The FDA first approved the molecule as Mounjaro in May 2022 for adults with type 2 diabetes, then as Zepbound in November 2023 for chronic weight management.
Because the drug is identical, prescribers sometimes substitute one brand for the other based on insurance coverage and indication. Your pharmacy label, however, will read whichever brand your clinician prescribed, and you should not switch without guidance.
Why Two Brands Exist
The US system generally requires that a specific brand match a specific FDA-approved use for insurance reimbursement. Splitting tirzepatide into two brands lets Lilly market and price the drug differently for diabetes versus obesity and lets payers apply coverage rules for each indication. It also simplifies patient education materials, because the counseling for someone with obesity differs from counseling for someone with diabetes, even when the molecule is the same.
Mounjaro vs Zepbound at a Glance
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA-approved use | Type 2 diabetes | Chronic weight management |
| Approval year | 2022 | 2023 |
| Dosing | 2.5 to 15 mg weekly | 2.5 to 15 mg weekly |
| Delivery | Pre-filled pen | Pre-filled pen and single-dose vial |
| Typical trial weight loss | Up to ~15% at 15 mg (SURPASS) | Up to ~20.9% at 15 mg (SURMOUNT-1) |
| Prescription required | Yes | Yes |
How Well It Works
In the SURMOUNT-1 trial (New England Journal of Medicine, 2022), adults with obesity and without diabetes who took tirzepatide 15 mg weekly for 72 weeks lost about 20.9% of their body weight, compared with 3.1% on placebo. In people with type 2 diabetes, the SURPASS program showed A1C reductions of 2.0 to 2.5 percentage points and mean weight loss of roughly 8 to 12 kg at higher doses. If you are in the A1C levels range associated with prediabetes, even partial weight loss can shift you back toward normal.
Side Effects and Warnings
Gastrointestinal effects are the most common issue during dose escalation. In trials, the most frequent adverse events were nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, and fatigue. Severe reactions include pancreatitis, gallbladder disease, acute kidney injury from dehydration, severe gastroparesis, and hypersensitivity reactions. Tirzepatide carries a boxed warning against use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Women of reproductive age should note that tirzepatide may reduce the effectiveness of oral contraceptives after starting or escalating doses; nonoral contraception or a barrier method is recommended for four weeks. Pregnancy, breastfeeding, and active pancreatitis are generally reasons to avoid the drug.
Who Might Consider Zepbound
Zepbound is indicated for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity. Good candidates usually:
- Have tried diet and activity changes without reaching their goal weight.
- Understand this is a long-term medication, not a quick fix.
- Can tolerate weekly self-injections and gradual dose escalation.
- Do not have contraindications such as a history of medullary thyroid cancer.
- Have support for lifestyle change, including the approach outlined in our diet and nutrition hub.
How It Fits With Lifestyle Care
The labeling for both Mounjaro and Zepbound specifies use alongside a reduced-calorie diet and increased physical activity. Clinical trials enrolled participants who received structured lifestyle counseling, so real-world results depend partly on replicating that. For someone focused on reversing prediabetes, pairing tirzepatide with sustainable changes in food, movement, and sleep is the pattern that supports the drug doing its job.
Insurance, Cost, and Access
Zepbound coverage varies widely. Many commercial plans cover it with prior authorization for weight management; Medicare generally does not cover anti-obesity drugs, although that is under active policy debate. Lilly has introduced single-dose vials at a lower list price to improve access for cash-paying patients. Telehealth services can prescribe Zepbound when appropriate, but any legitimate provider still requires an evaluation and follow-up.
The Bottom Line
Zepbound and tirzepatide are not two different things; they are the same drug with different branding. Zepbound is the weight-management label for tirzepatide, while Mounjaro is the type 2 diabetes label. The decision to use it is a clinical one based on BMI, comorbidities, contraindications, and goals, and it should always sit inside a broader plan that includes food, movement, and regular follow-up with a clinician.
This article is educational and does not replace medical advice. Discuss your personal risks and benefits with your clinician before starting or changing any prescription.
